Chemotherapy port placement in breast cancer patients in a resource constrained setting: hurdles and outcomes


  • Navin Rajendra Kasliwal Department of Surgery, MGM Medical College, Aurangabad, Maharashtra, India
  • Satish Sonawane Department of Surgery, Dr. PVP Medical College, Aurangabad, Maharashtra, India



Chemotherapy port, Breast cancer


Background: Safe long-term venous access is essential in cancer undergoing chemotherapy, bone marrow transplant or supportive management in some conditions. Implanted devices are of choice here but under-utilised. Our review focuses on evaluating the reasons for this underutilisation so as to promote the use of chemo port in specific situations.

Methods: 245 patients undergoing port placement in a socio-economically constrained zone were analysed with regard to multiple clinical, social and logistical parameters and long-term follow-up assessed.

Results: Solid malignancy was the most common indication for port placement followed by hemato-lymphoid cancers. Breast cancers are the commonest solid cancer for Port placement. In our evaluation patients having chemotherapy ports were less worried about the upcoming chemo procedures because of the ease of IV access, resulting in better compliance and quality of life. Cost of the device and absence of expertise for placement and handling were the primary reasons for reluctance of port placement. Port related complications were few, not life threatening, and insignificant in the long term.

Conclusions: Placement of a Chemotherapy port is a technique with an easy learning curve and a good safety profile. Procedural and long term complications are few and acceptable. Costs are acceptable in the long term and are beneficial to the patient. This method to needs to be promoted in patients needing long-term venous access. Adequate training will promote acceptance and use of the chemo-port. Clinicians should adopt and offer this for all indicated patients.

Author Biographies

Navin Rajendra Kasliwal, Department of Surgery, MGM Medical College, Aurangabad, Maharashtra, India

surgical oncologist and assistant professor

Satish Sonawane, Department of Surgery, Dr. PVP Medical College, Aurangabad, Maharashtra, India

Professor, Surgery


Niederhuber JE, Ensminger W, Gyves JW, Liepman M, Doan K, Cozzi E. Totally implanted venous and arterial access system to replace external catheters in cancer treatment. Surgery. 1982;92:706-712.

Souadka A, Essangri H, Boualaoui I, Ghannam A, Benkabbou A, Amrani L et al. Supraclavicular versus infraclavicular approach in inserting totally implantable central venous access for cancer therapy: A comparative retrospective study.PLoS One. 2020;15(11):e0242727.

Barbetakis N, Asteriou C, Kleontas A, Tsilikas C. Totally implantable central venous access ports. Analysis of 700 cases.J Surg Oncol. 2011;104(6):654-6.

Ahn, SJ, Kim, HC, Chung, JW. Ultrasound and fluoroscopy-guided placement of central venous ports via internal jugular vein: retrospective analysis of 1254 port implantations at a single center. Korean J Radiol. 2012;13:314-323.

Heibl C, Trommet V, Burgstaller S, Mayrbaeurl B, Baldinger C, Koplmüller R et al. Complications associated with the use of Port-a-Caths in patients with malignant or haematological disease: a single-centre prospective analysis. Eur J Cancer Care (Engl). 2010;19(5):676-81.

Iannacci L, Piomelli S. Supportive care for children with cancer. Guidelines of the Childrens Cancer Study Group. Use of venous access lines. Hematol Oncol. 1984;6(3):277-81.

Taber SW, Bergamini TM. Long-term venous access: indications and choice of site and catheter. Semin Vasc Surg. 1997;10(3):130-4.

Patel PM, Thakkar JM, Patel BM. Long term venous access catheter in cancer patients at GCRI. Guj Med J. 2010;65:1.

Kock HJ, Pietsch M, Krause U, Wilke H, Eigler FW. Implantable vascular access system: experience in 1500 patients with totally implanted central venous port systems. World J Surg. 1998;22:12-16.

Abraham SW, Bassi KK, Giri AK, Pandey KK, Pattanayak M. Totally implantable venous access ports: retrospective review of long-term complications in 81 patients. Indian J Cancer. 2012;49:114-118.

Biffi R, Toro A, Pozzi S, Di Carlo I. Totally implantable vascular access devices 30 years after the first procedure. What has changed and what is still unsolved? Support Care Cancer. 2014;22:1705-1714.

Tabatabaie O, Kasumova GG, Eskander MF, Critchlow JF, Tawa NE, Tseng JF. Totally implantable venous access devices: a review of complications and management strategies. Am J Clin Oncol. 2018;40:94-105.

Di Carlo I, Pulvirenti E, Mannino M, Toro A. Increased use of percutaneous technique for totally implantable venous access devices. Is it real progress? A 27-year comprehensive review on early complications. Ann Surg Oncol. 2010;17:1649-1656.






Original Research Articles